1887

Journal of General Virology header logo

Volume 86, Issue 1

Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology Free

Abstract

The interaction between human papillomavirus (HPV) particles and cell surface heparan sulfate requires intact conformation of the HPV particles. Type-specific HPV serology is currently based on virus-like particles (VLPs) with intact conformation. Presence of incorrectly folded VLPs in VLP preparations is recognized as an important cause of cross-reactivity in HPV serology. Heparin-coated microtitre plates were evaluated for capturing conformationally correct VLPs and improving the type specificity of HPV serology. Hybrid VLPs between HPV16 and HPV11, which had been found to have significant reactivity with children's sera and a batch of HPV18 VLPs that had failed the quality control because of significant reactivity with sera from virginal women, were tested in parallel with heparin ELISA, ordinary ELISA and type-specific mAb capture ELISA. Control sera from children that had detectable reactivity with HPV16/11 hybrid VLPs in ordinary ELISA did not react in heparin-based ELISA, but some hybrid VLPs also had background reactivity in capture ELISAs. Control sera from virginal women that had some reactivity with a poor quality HPV18 VLP preparation in ordinary ELISA had no reactivity in heparin or capture ELISA, suggesting that certain VLP preparations expose cross-reactive epitopes that are not exposed on VLPs with heparin-binding ability. As the sensitivity was similar or only marginally affected by the use of heparin plates, use of heparin-coated plates may improve the type specificity of VLP-based ELISAs and reduce interassay variability attributable to variable quality of different VLP batches.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80472-0
2005-01-01
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/1/vir860065.html?itemId=/content/journal/jgv/10.1099/vir.0.80472-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam V., Eklund C., Wang Z., Sapp M., Schiller J. T., Dillner J., Dillner L. 1999; A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 80:489–493 [CrossRef]
     [Google Scholar]
  2. Andersson-Ellstrom A., Dillner J., Hagmar B., Schiller J., Sapp M., Forssman L., Milsom I. 1996; Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23:234–238 [CrossRef]
     [Google Scholar]
  3. Carter J. J., Hagensee M. B., Lee S. K., McKnight B., Koutsky L. A., Galloway D. A. 1994; Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology 199:284–291 [CrossRef]
     [Google Scholar]
  4. Christensen N. D., Kreider J. W., Cladel N. M., Patrick S. D., Welsh P. A. 1990; Monoclonal antibody-mediated neutraliation of infectious human papillomavirus type 11. J Virol 64:5678–5681
     [Google Scholar]
  5. Combita A. L., Touze A., Bousarghin L., Sizaret P. Y., Munoz N., Coursaget P. 2001; Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 204:183–188 [CrossRef]
     [Google Scholar]
  6. Dillner J. 1999; The serological response to papillomaviruses. Semin Cancer Biol 9:423–430 [CrossRef]
     [Google Scholar]
  7. Drobni P., Mistry N., McMillan N., Evander M. 2003; Carboxy-fluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. Virology 310:163–172 [CrossRef]
     [Google Scholar]
  8. Galloway D. A., McDougall J. K. 1996; The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 7:309–315 [CrossRef]
     [Google Scholar]
  9. Giroglou T., Florin L., Schafer F., Streeck R. E., Sapp M. 2001; Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:1565–1570 [CrossRef]
     [Google Scholar]
  10. Grabowska K., Wang X., Jacobsson A., Dillner J. 2002; Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 271:1–15 [CrossRef]
     [Google Scholar]
  11. Heino P., Eklund C., Fredriksson-Shanazarian V., Goldman S., Schiller J. T., Dillner J. 1995; Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 87:437–440 [CrossRef]
     [Google Scholar]
  12. Joyce J. G., Tung J. S., Przysiecki C. T., Cook J. C., Lehman E. D., Sands J. A., Jansen K. U., Keller P. M. 1999; The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810–5822 [CrossRef]
     [Google Scholar]
  13. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. 1992; Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180–12184 [CrossRef]
     [Google Scholar]
  14. Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Barr E., Alvarez F. B., Chiacchierini L. M., Jansen K. U. 2002; A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651 [CrossRef]
     [Google Scholar]
  15. Ludmerer S. W., Benincasa D., Mark G. E. III 1996; Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 70:4791–4794
     [Google Scholar]
  16. Muller M., Gissmann L., Cristiano R. J., Sun X. Y., Frazer I. H., Jenson A. B., Alonso A., Zentgraf H., Zhou J. 1995; Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol 69:948–954
     [Google Scholar]
  17. Roden R. B., Kirnbauer R., Jenson A. B., Lowy D. R., Schiller J. T. 1994; Interaction of papillomaviruses with the cell surface. J Virol 68:7260–7266
     [Google Scholar]
  18. Roden R. B., Greenstone H. L., Kirnbauer R., Booy F. P., Jessie J., Lowy D. R., Schiller J. T. 1996; In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 70:5875–5883
     [Google Scholar]
  19. Roden R. B., Armstrong A., Haderer P., Christensen N. D., Hubbert N. L., Lowy D. R., Schiller J. T., Kirnbauer R. 1997; Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 71:6247–6252
     [Google Scholar]
  20. Rommel O., Dillner J., Fligge C., Bergsdorf C., Wang X., Selinka H. C., Sapp M. 2004; Heparan sulfate proteoglycans interact exclusively with conformationally intact HPVL1 assemblies: basis for a virus-like particle ELISA. J Med Virol 75:114–121
     [Google Scholar]
  21. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. 1993; Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus like particles. J Virol 67:1936–1944
     [Google Scholar]
  22. Rossi J. L., Gissmann L., Jansen K., Muller M. 2000; Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae . Hum Gene Ther 11:1165–1176 [CrossRef]
     [Google Scholar]
  23. Schiffman M. H., Bauer H. M., Hoover R. N. 7 other authors 1993; Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958–964 [CrossRef]
     [Google Scholar]
  24. Selinka H. C., Sapp M. 2003; Papillomavirus/cell-interactions initiating the infectious entry pathway. Papillomavirus Report 14:259–266 [CrossRef]
     [Google Scholar]
  25. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., Kirnbauer R. 2003; Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77:13125–13135 [CrossRef]
     [Google Scholar]
  26. Stauffer Y., Raj K., Masternak K., Beard P. 1998; Infectious human papillomavirus type 18 pseudovirions. J Mol Biol 283:529–536 [CrossRef]
     [Google Scholar]
  27. Studentsov Y. Y., Schiffman M., Strickler H. D., Ho G. Y. F., Pang Y.-Y. S., Schiller J., Herrero R., Burk R. D. 2002; Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 40:1755–1760 [CrossRef]
     [Google Scholar]
  28. Unckell F., Streeck R. E., Sapp M. 1997; Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 71:2934–2939
     [Google Scholar]
  29. Volpers C., Unckell F., Schirmacher P., Streeck R. E., Sapp M. 1995; Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol 69:3258–3264
     [Google Scholar]
  30. Walboomers J. M., Jacobs M. V., Manos M. M. 7 other authors 1999; Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19 [CrossRef]
     [Google Scholar]
  31. Wang Z., Christensen N., Schiller J. T., Dillner J. 1997a; A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78:2209–2215
     [Google Scholar]
  32. Wang Z., Konya J., Avall-Lundkvist E., Sapp M., Dillner J., Dillner L. 1997b; Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 52:436–440 [CrossRef]
     [Google Scholar]
  33. Wang Z. H., Kjellberg L., Abdala H. 11 other authors 2000; Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 181:456–462 [CrossRef]
     [Google Scholar]
  34. Wang X., Wang Z., Christensen N. D., Dillner J. 2003; Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. Virology 311:213–221 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80472-0
Loading
Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology
J. Gen. Virol. 86, 65 (2005); https://doi.org/10.1099/vir.0.80472-0
/content/journal/jgv/10.1099/vir.0.80472-0
/content/journal/jgv/10.1099/vir.0.80472-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error